In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history – a synchronized mass immune memory generated through SARS-CoV-2 infection and vaccination – into a powerful ally against cancer.

Published today in Nature Communications, the study introduces PROTEXI, an innovative dendritic cell vaccine platform designed to harness pre-existing antiviral immune memory to amplify the body's natural ability to recognize and destroy tumors.

Carbohydrate-based vaccines are an effective means for combating bacterial infections, particularly in the face of rising antibiotic resistance. This perspective provides an overview of carbohydrate vaccine against bacterial infections, from the earliest polysaccharide formulations to the latest synthetic constructs, and highlights the full engineering continuum encompassing carbohydrate antigen production, epitope mapping, conjugation chemistry, formulation, preclinical and clinical evaluation, and regulatory approval. By introducing the integrative framework of carbohydrate-based vaccine engineering (CVE), a unified perspective is provided to support both the optimization of current vaccine platforms and the rational design of next-generation glycoconjugate vaccines.